151 related articles for article (PubMed ID: 31421468)
21. Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Orita Y; Sugitani I; Toda K; Manabe J; Fujimoto Y
Thyroid; 2011 Jan; 21(1):31-5. PubMed ID: 21058881
[TBL] [Abstract][Full Text] [Related]
22. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial.
Kamba T; Kamoto T; Maruo S; Kikuchi T; Shimizu Y; Namiki S; Fujimoto K; Kawanishi H; Sato F; Narita S; Satoh T; Saito H; Sugimoto M; Teishima J; Masumori N; Egawa S; Sakai H; Okada Y; Terachi T; Ogawa O;
Int J Clin Oncol; 2017 Feb; 22(1):166-173. PubMed ID: 27614621
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China.
Yu Z; Liu Y; Cui Y; Ma R; Zhan H; Chen W; Liu H
J Comp Eff Res; 2019 May; 8(7):487-495. PubMed ID: 30922074
[No Abstract] [Full Text] [Related]
24. Prognostic value of early radiological response to first-line platinum-containing chemotherapy in patients with metastatic nasopharyngeal carcinoma.
Liu GY; Li WZ; Peng KQ; Lv X; Ke LR; Wu YS; Wang DL; Liang H; Liu KY; Lv SH; Guo X; Xiang YQ; Xia WX
Cancer Med; 2020 Feb; 9(3):920-930. PubMed ID: 31834990
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study.
Ueno S; Mizokami A; Fukagai T; Fujimoto N; Oh-Oka H; Kondo Y; Arai G; Ide H; Horie S; Ueki O; Kawaguchi K; Shimamura M; Orito M; Ishida T; Ikeda D; Namiki M
Anticancer Res; 2013 Sep; 33(9):3837-44. PubMed ID: 24023317
[TBL] [Abstract][Full Text] [Related]
26. First-Line Immunochemotherapy Versus Palliative Chemotherapy Plus Definitive Radiation Therapy for
Yang ZC; Liu T; Chen YZ; Guo CY; Liu LT; Liu SL; Chen QY; Mai HQ; Guo SS
Cancer Control; 2022; 29():10732748221124868. PubMed ID: 36047451
[TBL] [Abstract][Full Text] [Related]
27. Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: who will benefit from combined treatment?
Cao X; Han Y; He L; Xiang J; Wen Z
Oral Oncol; 2011 Aug; 47(8):747-52. PubMed ID: 21665523
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Wang Y; Tao H; Yu X; Wang Z; Wang M
Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
[TBL] [Abstract][Full Text] [Related]
29. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.
Velde NV; Wu EQ; Guo A; Lu M; Yu AP; Sharma H; Liu J; Fan CP; Shi L
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):79-84. PubMed ID: 21173792
[TBL] [Abstract][Full Text] [Related]
30. [Prognosis analysis of nasopharyngeal carcinoma patients with distant metastasis].
Wang CT; Cao KJ; Li Y; Xie GF; Huang PY
Ai Zheng; 2007 Feb; 26(2):212-5. PubMed ID: 17298756
[TBL] [Abstract][Full Text] [Related]
31. Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients.
Liang YJ; Sun XS; Yang ZC; Tang QN; Guo SS; Liu LT; Xie HJ; Liu SL; Yan JJ; Li XY; Chen QY; Mai HQ
Oral Oncol; 2019 May; 92():40-45. PubMed ID: 31010621
[TBL] [Abstract][Full Text] [Related]
32. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
33. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
[TBL] [Abstract][Full Text] [Related]
34. Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.
Nakai Y; Kanaki T; Yamamoto A; Tanaka R; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Ishibashi M; Nishimura K
J Bone Miner Metab; 2021 Mar; 39(2):295-301. PubMed ID: 32886176
[TBL] [Abstract][Full Text] [Related]
35. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy.
Sun XS; Liu LT; Liu SL; Guo SS; Wen YF; Xie HJ; Tang QN; Liang YJ; Li XY; Yan JJ; Ma J; Chen QY; Tang LQ; Mai HQ
BMC Cancer; 2019 Jan; 19(1):92. PubMed ID: 30665378
[TBL] [Abstract][Full Text] [Related]
36. Bone Metastases Pattern in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Real-World Analysis in the SEER Database.
Yang X; Ren H; Yu W; Li H; Yang X; Fu J
Biomed Res Int; 2020; 2020():2098325. PubMed ID: 32724795
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a novel MR imaging predictor of response to induction chemotherapy in locoregionally advanced nasopharyngeal cancer: a randomized controlled trial substudy (NCT01245959).
Dong D; Zhang F; Zhong LZ; Fang MJ; Huang CL; Yao JJ; Sun Y; Tian J; Ma J; Tang LL
BMC Med; 2019 Oct; 17(1):190. PubMed ID: 31640711
[TBL] [Abstract][Full Text] [Related]
38. Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials.
Chen C; Lin M; Yu D; Qin W; Zhou J; Guo L; Huang R; Fan X; Xiang S
PLoS One; 2022; 17(9):e0275176. PubMed ID: 36137135
[TBL] [Abstract][Full Text] [Related]
39. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
40. Platinum-based concurrent chemotherapy remains the optimal regimen for nasopharyngeal carcinoma: a large institutional-based cohort study from an endemic area.
Yu Y; Liang H; Lv X; Ke L; Qiu W; Huang X; Liu G; Li W; Guo X; Xiang Y; Xia W
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2231-2243. PubMed ID: 30109501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]